First human trial of CRISPR gets US panel’s nod

First human trial of CRISPR gets US panel’s nod

Washington, June 22 (IANS) For a study designed to target three types of cancer, a US advisory panel has approved the first human use of the groundbreaking gene-editing technology CRISPR, media reports said.

The proposed experiment is being funded by former Facebook President Sean Parker’s new cancer institute.

The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients’ own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma, the Washington Post reported on Tuesday.

The US National Institutes of Health’s Recombinant DNA Advisory Committee approved the proposal.

The experiment still must be approved by the Food and Drug Administration, which regulates clinical trials, the report said.

The Parker Institute for Cancer Immunotherapy aims to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease by ensuring the coordination and collaboration of the field’s top researchers.

The new study involves T cells – white blood cells essential for ridding the body of bacteria, malignancies and other invaders.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here